Nikolai Lorenzen did a PhD in the protein biophysics group of Professor Daniel Otzen at University of Aarhus , which concluded in 2014. Since then, he has been working within biophysics and injectable formulation in the early research organization at Novo Nordisk. After transitioning to industry he has continued to collaborate with academia and have published several scienticic publications within the field of antibody developability.